1.Tumor immunotherapy is applicable to a variety of solid tumors, including malignant melanoma, prostate cancer, kidney cancer, bladder cancer, ovarian cancer, colon cancer, rectal cancer, breast cancer, cervical cancer, lung cancer, laryngeal cancer, nasopharyngeal cancer, pancreatic cancer and other solid tumors to prevent recurrence after surgery, and also can be used for multiple myeloma, B-lymphoma and leukemia and other hematological malignancies to prevent recurrence, and also can be used for the further It can also be used for further consolidation treatment of these tumors to prolong survival, improve quality of life and inhibit tumor progression. However, biological therapy is not applicable to patients with T-cell lymphoma, long-term use of immunosuppressive drugs after organ transplantation and patients with autoimmune diseases who are using immunosuppressive drugs. 2.Tumor immunotherapy quickly restores the immune damage caused by surgery and improves the success rate of surgery; removes residual cancer cells after surgery and prevents metastasis and recurrence; reduces the immunosuppressive effect of chemotherapy drugs; enhances the tolerance of radiotherapy and reduces the toxic side effects of radiotherapy; reduces pain and improves the patient’s survival quality. The common concomitant reaction is fever, which mostly appears within 2-6 hours after immunocell infusion, with body temperature between 37.5℃ and 38.5℃. Most of the fever can subside automatically after 2 hours, but a few may develop chills and high fever. Generally, it can be relieved or prevented by physical cooling or routine use of non-steroidal anti-inflammatory drugs such as indomethacin before cell infusion, and in rare cases, there are upper respiratory tract infection-like symptoms, which can generally be relieved by themselves without special treatment. Other rare side effects include headache, nausea, muscle aches and pains, all of which are transient in nature.